GeneReach Biotechnology (4171) — Capital Reinvestment Ratio
GeneReach Biotechnology (4171) has a Capital Reinvestment Ratio of 0.38x as of December 2025, meaning it reinvests 0% of its operating cash flow (NT$12.05 Million) in capital expenditures (NT$4.58 Million). See GeneReach Biotechnology balance sheet quality to measure how much of total assets are equity-financed.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
GeneReach Biotechnology Capital Reinvestment Ratio (2018–2022)
This chart tracks GeneReach Biotechnology's Capital Reinvestment Ratio across 4 annual periods. Check 4171 cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Annual Capital Reinvestment Ratio for GeneReach Biotechnology (2018–2022)
Year-by-year Capital Reinvestment Ratio for GeneReach Biotechnology from 2018 to 2022. For live market cap and broader valuation context, see market cap of GeneReach Biotechnology.
| Year | Reinvestment Ratio | Operating CF (TWD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2022 | 0.13x | NT$357.63 Million | NT$44.90 Million | ▲ +177.5% |
| 2021 | 0.05x | NT$348.99 Million | NT$15.79 Million | ▼ -88.2% |
| 2020 | 0.38x | NT$169.82 Million | NT$64.87 Million | ▼ -4.9% |
| 2018 | 0.40x | NT$5.74 Million | NT$2.31 Million | — |